Skip to Content
Merck
CN

Key Documents

View All Documentation

P8396

Piperacillin sodium salt

penicillin analog

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C23H26N5NaO7S
CAS Number:
59703-84-3
Molecular Weight:
539.54
UNSPSC Code:
51282423
NACRES:
NA.85
PubChem Substance ID:
329820325
EC Number:
261-868-6
Beilstein/REAXYS Number:
5373920
MDL number:
MFCD00917471
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

200

form

powder

solubility

H2O: soluble 50 mg/mL

antibiotic activity spectrum

Gram-negative bacteria, Gram-positive bacteria

mode of action

cell wall synthesis | interferes

storage temp.

2-8°C

SMILES string

[Na+].CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C([O-])=O)c4ccccc4)C(=O)C1=O

InChI

1S/C23H27N5O7S.Na/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28;/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34);/q;+1/p-1/t13-,14-,15+,20-;/m1./s1

InChI key

WCMIIGXFCMNQDS-IDYPWDAWSA-M

General description

Chemical structure: β-lactam

Application

Piperacillin is a semisynthetic, broad-spectrum ureidopenicillin antibiotic. It is derived from ampicillin. It has been used in pharmacokinetic studies in order to optimize antimicrobial therapy in patients with sepsis. It is used to study piperacillin hypersensitivity reactions and to study multidrug-resistant organisms.

Biochem/physiol Actions

Piperacillin inhibits the last stage of bacterial cell wall synthesis by binding to certain penicillin-binding proteins (PBPs), which results in cell lysis. Cell lysis is mediated by bacterial cell wall autolytic enzymes. Piperacillin may interfere with autolysin inhibitors.

Packaging

1g,5g,10g

Other Notes

Keep container tightly closed in a dry and well-ventilated place.Keep in a dry place.

Still not finding the right product?

Explore all of our products under Piperacillin sodium salt

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Information

涉药品监管产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000225055
099M4897V
099M4896V
059M4831V
049M4832V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Grace C Lee et al.
Clinical therapeutics, 34(12), 2297-2300 (2012-12-01)
Studies evaluating the outcomes of an extended-infusion (EI) piperacillin-tazobactam dosing strategy in specific cohorts of critically ill patients are lacking. A retrospective, pre-implementation and post-implementation study of 148 critically ill patients was conducted to compare EI and traditional infusion piperacillin-tazobactam.
João Gonçalves-Pereira et al.
PloS one, 7(11), e49845-e49845 (2012-11-28)
The clinical efficacy of continuous infusion of piperacillin/tazobactam in critically ill patients with microbiologically documented infections is currently unknown. We conducted a retrospective multicenter cohort study in 7 Portuguese intensive care units (ICU). We included 569 critically ill adult patients
S Christian Cheatham et al.
International journal of antimicrobial agents, 41(1), 52-56 (2012-12-12)
The study objective was to evaluate steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. Fourteen hospitalised patients weighing >120kg received piperacillin/tazobactam 4.5 g every 8 h (q8h) or 6.75 g q8h infused over
View All Related Papers

Global Trade Item Number

SKUGTIN
P8396-1G04061834401377
P8396-10G04061834401360
P8396-5G04061834401384